CRP对接受WHO推荐照护方案的乌干达晚期HIV患者住院与死亡的预测价值
该前瞻性队列纳入1388例CD4≤200 cells/µL的乌干达门诊成人,其中1378例检测了基线CRP,均接受WHO推荐的结核与隐球菌筛查及治疗。41.6%的患者CRP≥10 mg/L,该组30天内住院相对风险为4.2(95%CI 2.3-7.8),死亡相对风险为9.8(95%CI 2.9-32.8)。
要点
- 晚期HIV门诊患者中41.6%基线CRP≥10 mg/L。
- CRP≥10 mg/L者30天住院风险增4.2倍、死亡风险增9.8倍。
- CRP每倍增,30天住院或死亡风险增36.9%(HR=1.4)。
核心结论
- 在CD4≤200 cells/µL且接受WHO推荐照护方案的乌干达门诊患者中,CRP≥10 mg/L与30天住院或死亡风险升高相关。
- 将CRP纳入多变量模型可显著改善对30天住院或死亡的预测。
研究设计与样本
- 前瞻性队列研究,2022年5月至2025年2月纳入1388例CD4≤200 cells/µL的乌干达门诊成人,其中1378例有基线血清CRP检测结果。
- 参与者为ART初治或经治者,排除已知病毒学抑制者,均按WHO建议接受结核与隐球菌筛查及治疗。
主要发现
- 1378例参与者中41.6%基线CRP≥10 mg/L。
- CRP≥10 mg/L者30天内住院相对风险为4.2(95%CI 2.3-7.8),死亡相对风险为9.8(95%CI 2.9-32.8)。
- 调整体重、CD4计数、ART状态和年龄后,CRP每2倍增加与30天住院或死亡风险增加36.9%相关(HR=1.4,95%CI 1.2-1.5)。
关键数值与推荐
- CRP dichotomized阈值为≥10 mg/L。
- CRP以连续变量(每2倍增加)和二分变量(≥10 mg/L)分别评估对30天住院或死亡的预测价值。
临床怎么用
- 对接受WHO推荐照护方案的晚期HIV门诊患者,可考虑检测CRP以识别30天住院或死亡高风险者。
- CRP≥10 mg/L提示需加强风险分层与随访,但需前瞻性研究验证床旁CRP检测能否降低AIDS相关死亡。
局限性
- 研究为观察性设计,CRP检测的干预价值需前瞻性研究验证。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with advanced human immunodeficiency virus (HIV) disease (CD4 ≤ 200 cells/µL) remain at high risk for opportunistic infections, hospitalization, and death, despite access to antiretroviral therapy (ART). We evaluated serum C-reactive protein (CRP) as a predictor of 30-day hospitalization or death among outpatients with advanced HIV disease. METHODS: We prospectively enrolled 1388 outpatient Ugandan adults with CD4 ≤ 200 cells/µL from May 2022 to February 2025, of whom 1378 had serum CRP measured at enrollment. Participants were ART-naïve or experienced, and people with known virologic suppression were excluded. Participants received tuberculosis and cryptococcosis screening and therapy per World Health Organization (WHO) recommendations. We examined CRP as a continuous and dichotomized predictor (≥10 mg/L) of 30-day hospitalization or death. RESULTS: Among 1378 participants, 41.6% had CRP ≥10 mg/L. Participants with CRP ≥10 mg/L were more likely to be hospitalized (relative risk = 4.2, 95% CI: 2.3-7.8) or die (relative risk = 9.8, 95% CI: 2.9-32.8) within 30 days. In a multivariable Cox model adjusted for weight, CD4 count, ART status, and age, each 2-fold increase in CRP was associated with a 36.9% higher hazard of 30-day hospitalization or death (hazard ratio = 1.4, 95% CI: 1.2-1.5). Including CRP in the multivariable model significantly improved prediction of 30-day hospitalization or death (AUC 0.80 with CRP vs 0.72 without, DeLong's P = .009). CONCLUSIONS: CRP ≥10 mg/L is associated with increased risk of 30-day hospitalization or death among outpatients with advanced HIV disease receiving the WHO-recommended package of care. Prospective studies should evaluate whether point-of-care CRP testing can enable real-time risk stratification to reduce AIDS-related deaths.
引用
- Schwartz EL, Nalintya EK, Skipper CP, et al. Predictive Value of C-reactive Protein for Hospitalization and Mortality Among People With Advanced HIV Disease in Uganda Receiving the World Health Organization-recommended Package of Care. Clin Infect Dis. 2026. PMID: 41057277. doi:10.1093/cid/ciaf560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。